The aim of this investigation was to evaluate the feasibility of a shortened whole breast irradiation schedule with a concomitant boost delivered to the tumor bed once a-week in patients with early breast cancer submitted to conservative surgery. Methods: This study included 48 female patients with early breast cancer who underwent breast conservative surgery. There were two arm of radiation, hypofractionated radiotherapy with concomitant boost (group A) -hypofractionated radiotherapy with sequential boost (group B). Results: Acute skin toxicity grade 1 (dry desquamation) was (41.67%) in concomitant boost arm and (25.00%) sequential boost arm. late skin toxicity ,grade 0 was (72.73%) in concomitant boost arm and (54.55%) in sequential boost arm and grade 1 was (9.09%) in concomitant boost arm and (31.82%) in sequential boost arm and grade 2 was (18.19) in concomitant boost arm and (13.55%) in sequential boost arm, grade 3 late lung toxicity was (4.17%) in concomitant boost arm and (12.50%) in sequential boost arm, cardiac toxicity in concomitant boost arm (8.33%) and sequential boost arm (16.67%).The ipsilateral lymphedema after 24 months of follow up G2 (4.55%) in concomitant boost arm G3 (4.55%) in in sequential boost arm. Conclusion: A shortened whole breast irradiation schedule with a weekly concomitant boost may be an alternative option with acceptable toxicity and excellent cosmesis.
Introduction
Radiation therapy after lumpectomy is a standard part of breast conserving therapy for invasive breast cancer as it has been shown that besides significantly reducing the risk of local recurrence, it impacts favorably on patient survival [1] . The possibility of delivering postoperative radiation therapy in a shorter period of time result in a dramatic reduction of the nuisance factor for these patients. The results of retrospective studies of hypofractionated radiotherapy in early breast cancer suggest satisfactory outcomes in terms of tumor control and late adverse effects [2] .The aim of this investigation was to evaluate the feasibility of a shortened whole-breast irradiation schedule delivered to the tumor bed once a-week in patients with early breast cancer.
Patients and Methods Patients and Methods
This prospective study included 48 female patients with early breast cancer. Who received adjuvant radiotherapy in the radiotherapy department in Sohage University Hospital, Egypt, in period between March, 2014 and July, 2018. Patients with age of 18 years and above, with all histological types and grades, pathological T1-T2 tumors,N0 and N1 disease with negative surgical margins after breast conservative surgery. Were eligible and written consent was taken from each patient then randomly Allocated into two groups. A-The total whole breast radiation dose was 42.5 Gy in 16 fractions while the area of the lumpectomy cavity received additional 3Gy through once weekly 1 Gy concomitant boost. B-The total whole breast radiation dose was 42.5 Gy in 16 fractions followed by sequential boost.
Radiation:
Patients treated in the supine position on a wedged board with both arm abducted and externally rotated. CT planning in CT simulation will patient in the same treatment position was used for the localization and determination of the target volumes, organ at risk, and the field arrangement. The CT scans were done in the supine position from the level of the larynx to the upper abdomen with both lungs were included and the scan thickness was 5 mm. The Whole Breast Clinical Target Volume (WB-CTV) included the glandular breast tissue. The Whole Breast Planning Target Volume (WB-PTV) was generated by the addition of a 5 mm margin around the WB-CTV. The Boost Clinical Target Volume (CB-CTV) was generated by adding at least a 10 mm margin around the lumpectomy cavity and the corresponding PTV (CB-PTV) created by adding a further 5 mm margin.. The total whole breast radiation dose was 42.5 Gy in 16 fractions while the area of the lumpectomy cavity received additional 3Gy through once weekly 1 Gy concomitant photon boost in group A or received additional 10-16 Gy a sequential boost in group B.
Assessment and Follow up:
Clinical evaluations were performed weekly during treatment course for assessment of acute toxicity. A followup evaluation was performed every three months after treatment end for evaluation of the late radiation toxicity, disease free survival and local control.. all patient evaluated by ECHO before radiotherapy and every 6 month after treatment to monitor change in left ventricular ejection friction in comparison with base line assment. The RTOG scoring system for radiation reactions was used to score radiation toxicity. 
Results

Discussion
Acute skin complication in our study were assessed during the treatment and up to 12 weeks, The incidence of grade 1 (dry desquamation) was (41.67%) in group A and (25.00%) in group B and grade 2 was (8.33%) in group A and (16.67%) in group B. but acute skin toxicity reported at Guenze et al [3] where grade 1(39%) grade 2 acute skin toxicity was 9 %. While Corvo et al [4] reported12 % of patients developed grade 2 acute skin toxicity so our results are comparable to that shown in the reported studies. In our study late skin toxicity 24 ms, the incidence of grade 0 was (72.73%) in group A and (54.55%) in group B and grade 1 was (9.09%) in group A and (31.82%) in group B and grade 2 was (18.19) in group A and (13.55%) in group B, but late skin toxicity reported at Guenze et al. [3] where G0 (52%) G1 (45%) G2 (3%) while late skin toxicity reported at Corvo et al [4] where G0 in 92%, G1 in 7% and G2 in 1% of patients, so our results are comparable to that shown in the reported studies as regard incidence of grade 1 late skin toxicity in group A . In our study, the acute radiation induced pnumonitis was reported as grade 2 was (4.17%) in both groups, while the chronic toxicity reported as grade 3 late lung toxicity was (4.17%) in group A and (12.50%) in group B. These results also are comparable to those reported by Shahid et al [5] , where 5% of patients developed acute pulmonary radiation toxicity and ElHadaad et al [6] grade 1 late lung toxicity was 5.5%. In our study, the cardiac toxicity was evaluated by measuring the left ventricular ejection fraction at base line and every 6 months after radiotherapy. In our study we had only two patients in group A (8.33%) and four patients in group B (16.67%) who showed drop more than 10% below the base line left ventricular ejection fraction (LVEF). while Shahid et al [5] reported that cardiac toxicity occurred in 5% to 6% of patients between the three hypo fractionated schedules so our patients showed more toxicity as most of patients received anthracyclin combined with taxan based chemotherapy and tamoxifen as hormonal treatment and some patients received trastuzomab contaning regmin Regarding the ipsilateral lymphedema, in our study 12 at months of follow up G1 lymphedema (8.33%) in group A (4.17%) in group B, G2 moderate lymphedema (12.50%) in group A (4.17%) in groupB. After 24 months of follow up G2 moderate lymphedema (4.55%) in group A G3 severe lymphedema (4.55%) in groupB while Shahid et al [5] reported that G2 and G3 lymphedoema was 21%, 22% and 27% between the three hypo fractionated schedules. recently published systematic review and meta-analysis on the incidence of unilateral lymphedema after breast cancer where a pooled estimate of lymphedema in the 72 studies showed an incidence of edema of 16.6% as reported by Disipio et al [6] .Our lower rates of lymphedema toxicity may be due to avoid using axillary radiation in separate fields in node positive patients. 
